Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Nacer Lounis"'
Autor:
Jingtao Gao, Mengqiu Gao, Jian Du, Yu Pang, Gary Mao, Nacer Lounis, Nyasha Bakare, Yanxin Jiang, Ying Zhan, Yuhong Liu, Liang Li, on behalf of the Trial Team
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Introduction The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has significantly impeded TB control efforts in China. Methods This phase 4, ra
Externí odkaz:
https://doaj.org/article/544d1e18c34f41158330125060aec91d
Autor:
Aurélie Chauffour, Nacer Lounis, Koen Andries, Vincent Jarlier, Nicolas Veziris, Alexandra Aubry
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 11, p e0011379 (2023)
BackgroundBedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of BDQ administered orally, (
Externí odkaz:
https://doaj.org/article/23001d8abd804ff4afba75c4cf2f112b
Autor:
Paul Meyvisch, Chrispin Kambili, Koen Andries, Nacer Lounis, Myriam Theeuwes, Brian Dannemann, An Vandebosch, Wim Van der Elst, Geert Molenberghs, Ariel Alonso
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0200539 (2018)
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for
Externí odkaz:
https://doaj.org/article/03094ade65714b5fa70d067772889bc2
Autor:
Koen Andries, Cristina Villellas, Nele Coeck, Kim Thys, Tom Gevers, Luc Vranckx, Nacer Lounis, Bouke C de Jong, Anil Koul
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e102135 (2014)
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non
Externí odkaz:
https://doaj.org/article/4e20d166193842fdbc285fe8879fc250
Publikováno v:
PLoS ONE, Vol 6, Iss 3, p e17556 (2011)
RationaleThe sterilizing activity of the regimen used to treat multidrug resistant tuberculosis (MDR TB) has not been studied in a mouse model.Objective and methodsSwiss mice were intravenously inoculated with 6 log10 of Mycobacterium tuberculosis (T
Externí odkaz:
https://doaj.org/article/5b41338aa1a849aea4a30571471ea535
Autor:
Aurélie Chauffour, Nacer Lounis, Koen Andries, Vincent Jarlier, Nicolas Veziris, Alexandra Aubry
BackgroundBedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of oral BDQ, (ii) evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2abd6a7ae3fcd4f24c76cd1243882b4
https://doi.org/10.1101/2023.05.15.540907
https://doi.org/10.1101/2023.05.15.540907
Autor:
Devinder Kaur, Daniela Maria Cirillo, Amour Venter, Nacer Lounis, Beverly Metchock, Koné Kaniga, Sven Hoffner, Nazir Ahmed Ismail, Gaby E. Pfyffer
Publikováno v:
Journal of Clinical Microbiology. 54:2956-2962
The aim of this study was to establish standardized drug susceptibility testing (DST) methodologies and reference MIC quality control (QC) ranges for bedaquiline, a diarylquinoline antimycobacterial, used in the treatment of adults with multidrug-res
Autor:
Daniela Maria Cirillo, Sven Hoffner, Nazir Ahmed Ismail, Gaby E. Pfyffer, Nacer Lounis, Beverly Metchock, Koné Kaniga, Devinder Kaur, Amour Venter
Publikováno v:
Journal of Clinical Microbiology. 54:2963-2968
Our objective was to establish reference MIC quality control (QC) ranges for drug susceptibility testing of antimycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Health Organization category 5 drugs for
Autor:
Anandi Martin, Isabel Torres Godino, Diana Angelica Aguilar-Ayala, Vanessa Mathys, Nacer Lounis, Hector Rodriguez Villalobos
Publikováno v:
Journal of medical microbiology. 68(8)
Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown. The objective of this study was to determine the in vitro activity
Publikováno v:
Advances in Tuberculosis Medicinal Chemistry. :120-133